Frequency of CV-related Hospitalizations1,5,6
| CV-related Hospitalizations Frequency During 30 Months |
CV-related Hospitalizations
Per Year
Pooled Tafamidis n=264
Placebo n=177
Relative risk reduction
32%
Relative risk ratio: 0.68 (0.56-0.81);
p<0.0001
Analysis not adjusted for multiplicity.
|
|
|
| Characteristic |
Total number of
patients with CV-related
hospitalizations (%) |
Pooled Tafamidis
(N=264) |
138 (52.3) |
Placebo
(N=177) |
107 (60.5) |
Patient-years of treatment needed: 4.4*
~4 patient-years of treatment needed to prevent 1
CV-related
hospitalization1 |
| *Based on NNT calculation, adapted for CV-related hospitalizations as a recurring event. |
|
